The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Compound

tirzepatide

Dual GIP and GLP-1 receptor agonist.

73 topics 20 solved Synonyms: tirz, tzp Group: Compound

Related in this group: semaglutide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues

73 topics · page 2 of 3

TopicParticipantsRepliesViewsActivity
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version
On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med ,…
SCCHOLNVKB+85 90 13k 7mo
Tirzepatide's shorter half-life and its one practical consequence
On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
RERMNECCB+18 29 20k 8mo
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…
DVKAOARNGR+4 8 14k 8mo
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still have a…
KDEJMSKP+127 137 32k 8mo
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med ,…
APSKIAOOCV+89 101 32k 8mo
Follow-up: The lowest dose that does anything: is that a real question?
The question in the title: The lowest dose that does anything: is that a real question? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still…
SCYAJWEHYM+70 75 12k 8mo
Revisiting: GLP-1 receptor distribution: central and peripheral
Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…
RTHFDTIBRM+61 66 15k 8mo
Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 8 (…
LERWMHKMBR+18 22 37k 8mo
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
KTVSMNARF 4 32k 8mo
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A documentation question rather than an analytical one. I have a certificate in front of me that reports a…
CRRWMHKMN+86 90 61k 9mo
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a certificate in front…
SGBCTNNATT+22 26 1.8k 9mo
Dose numbers across compounds are not on the same scale
Dose numbers across compounds are not on the same scale — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I am asking…
BPISC 2 1.6k 9mo
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? A question about technique rather than about dose. I have been…
MAEKSS 2 8.9k 9mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on
Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…
GOGTMMDSRM+122 136 48k 9mo
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept Reporting something rather than asking about it, in case the pattern…
BWSANTIRSS+7 11 26k 9mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version
Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Comparing PIONEER 6 ( N Engl J Med ,…
KBCHGHECGI+48 52 609 10mo
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three replies will otherwise…
ACQZES 2 867 10mo
Escalating every six weeks instead of four: what I observed over eight months — one year on
On the subject in the title: Escalating every six weeks instead of four: what I observed over eight months — one year on Working notes rather than a conclusion. I have read the maintained page on this and I…
KHMPLSEVLP+55 59 9.1k 10mo
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
ISSSAKIR+35 39 547 11mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual
SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022)…
NSLMAADKA 4 42k 11mo
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…
AKTLAW 2 136 11mo
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think…
TTSIKR 2 58k 11mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 2 ( Lancet ,…
KHSCGIMYG+150 163 22k 11mo
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
POCCMH 2 31k 13mo
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
KRBSKSBCD+5 9 44k 13mo
About the Tirzepatide category
Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
SLTVDNSRM+2 6 132 13mo
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…
OVJSRPTS+115 130 44k 13mo
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
SDDMTBBTAM+38 44 6.6k 14mo
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
RFNRHC 2 763 15mo
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…
EKHFSB 2 56k 16mo